325 related articles for article (PubMed ID: 29565815)
1. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
[TBL] [Abstract][Full Text] [Related]
2. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
3. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
Sato T; Akao K; Sato A; Tsujimura T; Mukai S; Sekido Y
Cancer Med; 2023 Jun; 12(12):13586-13598. PubMed ID: 37165917
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068
[TBL] [Abstract][Full Text] [Related]
6. Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells.
Takehara Y; Yamochi T; Nagumo T; Cho T; Urushibara F; Ono K; Fujii T; Okamoto N; Sasaki Y; Tazawa S; Honma M; Norose T; Shiozawa E; Tate G; Takimoto M
Oncol Lett; 2018 May; 15(5):6825-6830. PubMed ID: 29731861
[TBL] [Abstract][Full Text] [Related]
7. NF2 alteration in mesothelioma.
Sekido Y; Sato T
Front Toxicol; 2023; 5():1161995. PubMed ID: 37180489
[TBL] [Abstract][Full Text] [Related]
8. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
Sekido Y
Pathol Int; 2011 Jun; 61(6):331-44. PubMed ID: 21615608
[TBL] [Abstract][Full Text] [Related]
10. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
12. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
13. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
[TBL] [Abstract][Full Text] [Related]
14. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
15. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Sato T; Sekido Y
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
[TBL] [Abstract][Full Text] [Related]
16. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
[TBL] [Abstract][Full Text] [Related]
17. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
[TBL] [Abstract][Full Text] [Related]
18. Expression and significance of Hippo/YAP signaling in glioma progression.
Zhang H; Geng D; Gao J; Qi Y; Shi Y; Wang Y; Jiang Y; Zhang Y; Fu J; Dong Y; Gao S; Yu R; Zhou X
Tumour Biol; 2016 Oct; ():. PubMed ID: 27718125
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
20. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
